The patent has been granted The patent has been granted, Grant of patent is intended, Examination is in progress, Request for examination was made, The application has been published EP Register Verified

NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM

Publication No. EP4079311

•

App No. EP21169363

•

Filed by Nuvamid SA

•

Filed on 2021-04-20

•

Issued/Published on 2025-10-01

Official EPO Register

Publication No. EP4079311 A1

Application No. EP21169363 Filed: 2021-04-20

Grant Date 2025-10-01 Mention of grant

Active Oppositions 1 Active EPO Oppositions

Patent Abstract / Summary

[0001] The invention relates to compounds of formula (I) and/or of formula (Ia) for the prevention and/or treatment of depression and/or anxiety related to a Parkinsonism such as an alpha-synucleinopathy as well as compositions and kit of parts comprising the same.

IPC Classifications

A61K31/706, A61P25/16, A61K31/7084, A61P25/24

Priority Claims

No priority claims recorded

Designated Contracting States (38 EPC States)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Parties & Representation

Applicants

Nuvamid SA

Route de la Corniche 3 A, 1066 Epalinges

Inventors (2)

BERMOND, Guillaume

13007 MARSEILLE

GARCON, Laurent

13960 SAUSSET LES PINS

Representatives / Agents

August Debouzy

7, rue de Téhéran, 75008 Paris

Schlich

9 St Catherine's Road, Littlehampton

Key Procedural Dates

Request-For-Examination 2023-04-17

Mention Of Grant Published 2025-10-01

First-Examination-Report-Despatched 2024-07-18

Legal Status & Event History

Official European Patent Office legal and procedural status changes recorded for this file.

42 Events Recorded

Date	Code	Event Description	Auth
2022-10-26	AK	DESIGNATED CONTRACTING STATES	EP
2022-09-23	PUAI	PUBLIC REFERENCE MADE UNDER ARTICLE 153(3) EPC TO A PUBLISHED INTERNATIONAL APPLICATION THAT HAS ENTERED THE EUROPEAN PHASE	EP
2022-09-23	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2023-04-21	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2023-05-24	17P	REQUEST FOR EXAMINATION FILED	EP
2023-05-24	RBV	DESIGNATED CONTRACTING STATES (CORRECTED)	EP
2024-07-19	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2024-08-21	17Q	FIRST EXAMINATION REPORT DESPATCHED	EP
2025-02-14	TPAC	OBSERVATIONS FILED BY THIRD PARTIES	EP
2025-04-25	GRAP	DESPATCH OF COMMUNICATION OF INTENTION TO GRANT A PATENT	EP
2025-04-25	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2025-05-28	INTG	INTENTION TO GRANT ANNOUNCED	EP
2025-08-22	GRAS	GRANT FEE PAID	EP
2025-08-29	GRAA	(EXPECTED) GRANT	EP
2025-08-29	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2025-10-01	AK	DESIGNATED CONTRACTING STATES	EP
2025-10-01	REG	REFERENCE TO A NATIONAL CODE	EP
2025-10-23	REG	REFERENCE TO A NATIONAL CODE	EP
2025-11-05	REG	REFERENCE TO A NATIONAL CODE	EP
2025-11-19	U01	REQUEST FOR UNITARY EFFECT FILED	EP
2025-11-26	U07	UNITARY EFFECT REGISTERED	EP
2025-12-02	REG	REFERENCE TO A NATIONAL CODE	EP
2025-12-03	RAP4	PARTY DATA CHANGED (PATENT OWNER DATA CHANGED OR RIGHTS OF A PATENT TRANSFERRED)	EP
2025-12-03	U1H	NAME OR ADDRESS OF THE PROPRIETOR CHANGED AFTER THE REGISTRATION OF THE UNITARY EFFECT	EP
2025-10-22	REG	REFERENCE TO A NATIONAL CODE	EP
2026-04-09	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-04-13	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-04-14	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-04-17	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-04-20	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-04-23	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-04-29	U20	RENEWAL FEE FOR THE EUROPEAN PATENT WITH UNITARY EFFECT PAID	EP
2026-04-24	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-05-01	REG	REFERENCE TO A NATIONAL CODE	EP
2026-07-03	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-03	PLBI	OPPOSITION FILED	EP
2026-07-08	REG	REFERENCE TO A NATIONAL CODE	EP
2026-07-12	PLAX	NOTICE OF OPPOSITION AND REQUEST TO FILE OBSERVATION + TIME LIMIT SENT	EP
2026-07-16	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-25	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-08-05	26	OPPOSITION FILED	EP
2026-10-10	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP

Patent & Non-Patent Citations

Cited documents and prior art referenced in search and examination reports.

46 Citations

Cited Patent Documents

WO0114424

Espacenet

WO0037504

Espacenet

US4256108

Espacenet

US4166452

Espacenet

US4265874

Espacenet

WO2017079195

Espacenet

US10611790

Espacenet

WO2018039207

Espacenet

WO2006105440 2006-10-05

Espacenet

EP3323415 2018-05-23

Espacenet

WO2016149277 2016-09-22

Espacenet

WO2017147058 2017-08-31

Espacenet

WO2019152416 2019-08-08

Espacenet

WO2020113811 2020-06-11

Espacenet

WO2022223612

Espacenet

Non-Patent Scientific Literature (NPL)

- "10th International Classification of Diseases (ICD 10", OFFICIAL BULLETIN NO 2020/9, Retrieved from the Internet <URL:https://www.atih.sante.fr/sites/default/files/public/content/3706/cim-102020bo.pdf>

- WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546

- BETTER ET AL., SCIENCE, vol. 240, 1988, pages 1041 - 1043

- SUN ET AL., PROC NATL ACAD SCI USA, vol. 84, 1987, pages 3439 - 3443

- LIU ET AL., J LMMUNO, vol. 139, 1987, pages 3521 - 3526

- NISHIMURA ET AL., CANCER RES, vol. 47, 1987, pages 999 - 1005

- WOOD ET AL., NATURE, vol. 314, 1985, pages 446 - 449

- SHAW ET AL., JNATL CANCER INST, vol. 80, 1988, pages 1553 - 1559

- HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448

- JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525

- REICHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329

- PRESTA, CURR. OP. STRUCT. BIOI., vol. 2, 1992, pages 593 - 596

- KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH

- CHOTHIALESK, J. MOL. BIOI., vol. 196, 1987, pages 901 - 917

- G.K.WENNING ET AL., MOVEMENT DISORDERS, vol. 19, no. 12, 2004, pages 1391 - 1402

- ANETTE SCHRAG ET AL., MOVEMENT DISORDERS, vol. 22, no. 16, December 2007 (2007-12-01), pages 2332 - 8, Retrieved from the Internet <URL:https://doi.org/10.1002/mds.21649>

- LEI LU, TANG LE, WEI WENSHI, HONG YUNYI, CHEN HEYU, YING WEIHAI, CHEN SHENGDI: "Nicotinamide mononucleotide improves energy activity and survival rate in an in vitro model of Parkinson's disease", EXPERIMENTAL AND THERAPEUTIC MEDICINE, 14 July 2014 (2014-07-14), GR , XP055311369, ISSN: 1792-0981, DOI: 10.3892/etm.2014.1842

- XIE XIAOXIAN; YU CHUNAN; ZHOU JIAFENG; XIAO QINGFENG; SHEN QICHEN; XIONG ZE; LI ZEZHI; FU ZHENGWEI: "Nicotinamide mononucleotide ameliorates the depression-like behaviors and is associated with attenuating the disruption of mitochondrial bioenergetics in depressed mice", JOURNAL OF AFFECTIVE DISORDERS, vol. 263, 15 February 2020 (2020-02-15), NL , pages 166 - 174, XP009529968, ISSN: 0165-0327, DOI: 10.1016/j.jad.2019.11.147

- BENDER ET AL: "Inhibition in vitro of the enzymes of the oxidative pathway of tryptophan metabolism and of nicotinamide nucleotide synthesis by benserazide, carbidopa and isoniazid", BIOCHEMICAL PHARMACOLOGY, ELSEVIER, US, vol. 29, no. 5, 1 March 1980 (1980-03-01), pages 707 - 712, XP025514122, ISSN: 0006-2952, [retrieved on 19800301], DOI: 10.1016/0006-2952(80)90544-4

- ANNA KA YEE KWONG ET AL: "Catalysis-Based Inhibitors of the Calcium Signaling Function of CD38", BIOCHEMISTRY, vol. 51, no. 1, 10 January 2012 (2012-01-10), pages 555 - 564, XP055078673, ISSN: 0006-2960, DOI: 10.1021/bi201509f

- KISS TAMAS ET AL: "Nicotinamide mononucleotide (NMN) treatment attenuates oxidative stress and rescues angiogenic capacity in aged cerebromicrovascular endothelial cells: a potential mechanism for the prevention of vascular cognitive impairment", GEROSCIENCE, SPRINGER INTERNATIONAL PUBLISHING, CHAM, vol. 41, no. 5, 29 May 2019 (2019-05-29), pages 619 - 630, XP036952852, ISSN: 2509-2715, [retrieved on 20190529], DOI: 10.1007/S11357-019-00074-2

- LEI LU ET AL: "Nicotinamide mononucleotide improves energy activity and survival rate in an in vitro model of Parkinson's disease", EXPERIMENTAL AND THERAPEUTIC MEDICINE, 14 July 2014 (2014-07-14), GR, XP055311369, ISSN: 1792-0981, DOI: 10.3892/etm.2014.1842

- CHANDRASEKARAN KRISH ET AL: "Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons.", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 26 MAY 2020, vol. 21, no. 11, 26 May 2020 (2020-05-26), XP009529952, ISSN: 1422-0067

- SHENGJUN WANG ET AL: "Design, Synthesis and SAR Studies of NAD Analogues as Potent Inhibitors towards CD38 NADase", MOLECULES, vol. 19, no. 10, 29 October 2014 (2014-10-29), DE, pages 15754 - 15767, XP055707855, ISSN: 1433-1373, DOI: 10.3390/molecules191015754

- SCHWARZ J ET AL: "Depression in Parkinson's disease", JOURNAL OF NEUROLOGY, STEINKOPFF-VERLAG, DE, vol. 258, no. 2, 11 May 2011 (2011-05-11), pages 336 - 338, XP019901208, ISSN: 1432-1459, DOI: 10.1007/S00415-011-6048-3

- LEI LU, TANG LE, WEI WENSHI, HONG YUNYI, CHEN HEYU, YING WEIHAI, CHEN SHENGDI: "Nicotinamide mononucleotide improves energy activity and survival rate in an in vitro model of Parkinson's disease", EXPERIMENTAL AND THERAPEUTIC MEDICINE, SPANDIDOS PUBLICATIONS, GR, 14 July 2014 (2014-07-14), GR , XP055311369, ISSN: 1792-0981, DOI: 10.3892/etm.2014.1842

- XIE XIAOXIAN; YU CHUNAN; ZHOU JIAFENG; XIAO QINGFENG; SHEN QICHEN; XIONG ZE; LI ZEZHI; FU ZHENGWEI: "Nicotinamide mononucleotide ameliorates the depression-like behaviors and is associated with attenuating the disruption of mitochondrial bioenergetics in depressed mice", JOURNAL OF AFFECTIVE DISORDERS., ELSEVIER BIOCHEMICAL PRESS, AMSTERDAM., NL, vol. 263, 15 February 2020 (2020-02-15), NL , pages 166 - 174, XP009529968, ISSN: 0165-0327, DOI: 10.1016/j.jad.2019.11.147

- GILMOUR BRIAN C.; GUDMUNDSRUD RUBEN; FRANK JOHANNES; HOV AMUND; LAUTRUP SOFIE; AMAN YAHYAH; RøSJø HELGE; BRENNER CHARLES: "Targeting NAD+ in translational research to relieve diseases and conditions of metabolic stress and ageing", MECHANISMS OF AGEING AND DEVELOPMENT., ELSEVIER SEQUOIA, LAUSANNE,, CH, vol. 186, 15 January 2020 (2020-01-15), CH , XP086054592, ISSN: 0047-6374, DOI: 10.1016/j.mad.2020.111208

- LAUTRUP SOFIE; SINCLAIR DAVID A.; MATTSON MARK P.; FANG EVANDRO F.: "NAD+ in Brain Aging and Neurodegenerative Disorders", CELL METABOLISM, CELL PRESS, UNITED STATES, vol. 30, no. 4, 1 October 2019 (2019-10-01), United States , pages 630 - 655, XP085846858, ISSN: 1550-4131, DOI: 10.1016/j.cmet.2019.09.001

- LU ET AL.: "Nicotinamide mononucleotide improves energy activity andsurvival rate in an in vitro model of Parkinson's diseas", EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: 943-950, 2014, 2014

- XIE ET AL.: "Nicotinamide mononucleotide ameliorates the depression-like behaviorsand is associated with attenuating the disruption of mitochondrialbioenergetics in depressed mice", JOURNAL OF AFFECTIVE DISORDERS 263 (2020) 166-174, 2020

Worldwide Patent Family

Related applications and patents in the same INPADOC worldwide family.

9 Family Members

Country	Publication Number	Kind	Publication Date	Action
EP	EP4079311A1	A1	2022-10-26	Espacenet
EP	EP4079311B1	B1	2025-10-01	Espacenet
EP	EP4079311C0	C0	2025-10-01	Espacenet
CA	CA3217516A1	A1	2022-10-27	Espacenet
CA	CA3217516C	C	2025-05-27	Espacenet
CN	CN117255689A	A	2023-12-19	Espacenet
US	US20240116971A1	A1	2024-04-11	Espacenet
US	US20240417421A1	A1	2024-12-19	Espacenet
WO	WO2022223613A1	A1	2022-10-27	Espacenet

Official File Inspection EPC Art. 128 Public Dossier

Complete European Patent Register Dossier (148 Total Documents)

The full inspection file for Application EP21169363 contains 148 total documents, including all notices of opposition, proprietor counter-statements, examination communications, third-party observations, and procedural forms. Below are all major recorded procedural filings and publication specifications.

Open 148-Doc Register Dossier

Dossier Filing

Date: 2025-10-31 Procedure: Examination 0009299APPR

Inspect on Register

NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM

Patent Abstract / Summary

IPC Classifications

Priority Claims

Designated Contracting States (38 EPC States)

Parties & Representation

Applicants

Inventors (2)

Representatives / Agents

Key Procedural Dates

Patent Oppositions

Schlich Ltd

Legal Status & Event History

Patent & Non-Patent Citations

Cited Patent Documents

Non-Patent Scientific Literature (NPL)

Worldwide Patent Family

Complete European Patent Register Dossier (148 Total Documents)

Recorded Filings & Patent Specifications

European Patent Specification - Granted Patent (B1)

Official European Patent Register Full Dossier

European Patent Application with Search Report (A1)

Lapse of the patent in a contracting state

Invitation to proprietor to file observations on the notice of opposition

New entry: Communication of a notice of opposition and request to file observations + time limit

Lapse of the patent in a contracting state

Opposition filed

Lapse of the patent in a contracting state

Lapse of the patent in a contracting state

Lapse of the patent in a contracting state

Change - applicant

(Expected) grant

New entry: Payment of fee for grant

New entry: Payment of fee for publishing/printing

New entry: Receipt of the translation of the claim(s)

New entry: Communication of intention to grant a patent

New entry: Renewal fee paid

Intention to grant the patent

Renewal fee payment

Change - German title

Change - English title

Change - French title

New entry: Observations by third parties

Observations by a third party

New entry: Reply to examination report

Change: Despatch of examination report + time limit

First examination report

New entry: Despatch of examination report + time limit

Communication from the examining division

New entry: Renewal fee paid

Renewal fee payment

The date on which the examining division becomes responsible, has been established

Request for examination filed

Change - designated states

Amendment by applicant

Date on which the examining division has become responsible

Amendments

New entry: Renewal fee paid

Renewal fee payment

Publication in section I.1 EP Bulletin

Change - representative

Language of the procedure

International searching authority